Telitacicept Reduces Proteinuria in IgA Nephropathy: Phase 3 Interim Analysis

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis globally, often progressing to end-stage renal disease [1, 2, 3]. Despite supportive care with blood pressure control and renin-angiotensin system inhibitors, many adults with IgAN exhibit persistent proteinuria, a key indicator of high risk for renal function decline [4, 5]. The pathogenesis, which involves B-cell activation and the production of pathogenic galactose-deficient IgA1, has become a focus for targeted immunomodulatory therapies [6, 7]. While several agents are in development, optimal strategies for slowing disease progression remain an area of active investigation [8, 9, 10]. A recent phase 3 trial now provides data on a therapy designed to inhibit two central B-cell signaling pathways.